For the second year in a row, the Alzheimer’s Drug Discovery Foundation (ADDF) has been chosen as Official Charity Partner of the 2016 TCS New York City Marathon. The race will take place on Sunday, November 6, 2016.
Grants awarded in the first two months of 2016 support researchers in the U.S. and Middle East pursuing drug programs, prevention studies, and research to accelerate clinical trials.
The Alzheimer's Drug Discovery Foundation (ADDF) has joined the BIRAX Initiative, which recently issues its third call for proposals. BIRAX brings together British and Israeli scientists to tackle some of the world’s most challenging diseases including cardiovascular and liver disease, diabetes and Parkinson’s.
We are partnering with PsychoGenics Inc. to bring its services to our grantees working on preclinical Alzheimer’s drug discovery programs.
Funded Researchers are pursuing diverse targets to treat Alzheimer's Disease.
At the December joint meeting, the ADDF Boards of Governors and Overseers welcomed seven new members.
On Monday, November 9, Margaret and Daniel Loeb received The Charles Evans Award from the ADDF at our Sixth Annual Fall Symposium & Luncheon. Thanks to the generosity of our donors, the Symposium & Luncheon raised more than $1 million, the most in the event’s history.
AlzeCure Foundation announced today that it has been awarded a grant from the ADDF to support the further development of its small molecule neurorestorative project.
Dr. Longo’s pioneering approach may soon lead to new disease modifying drugs.
The Foundation for Mitochondrial Medicine (FMM) is hosting its Hope Flies Health Series Webinar: Research Connecting Alzheimer’s and Mitochondrial Disease on Wednesday, September 23, 2015. The Foundation developed the webinar with partners including the ADDF, MitoAction and Sharecare to particularly bring greater awareness to mitochondrial disease in conjunction with Global Mitochondrial Disease Awareness Week.